Immunotherapy of Human Ovarian Carcinoma With OVAREX MAb-B43.13 in a HU-PBL-SCID/BG Mouse Model

According to an abstract submitted by the authors to the International Meeting on Idiotypic Network and Tumor Therapy by Gene Therapy and Drug Targeting, held March 6-7, 1998, in Bonn, Germany, "The monoclonal antibody B43.13, binding to the ovarian cancer-associated antigen CA125, has been injected into more than 200 patients with ovarian cancer in order to detect recurrence of the disease. The follow-up of the patients revealed surprisingly long survival spans for several patients despite high CA125 levels. In order to investigate the therapeutic effectiveness, OVAREX MAb-1343.13 was tested in a human-PBLSCID/BG mouse model. Mice were reconstituted with human PBL (normal donors) by...

Want to see the full article?

• Purchase this article for only $3.00